FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      
1. Name and Address of Reporting Person * Burnett Patrick 2. Issuer Name and Ticker or Trading Symbol Arcutis Biotherapeutics, Inc. [ ARQT ] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable)_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
See Remarks
(Last)         (First)         (Middle)
C/O ARCUTIS BIOTHERAPEUTICS, INC., 2945 TOWNSGATE ROAD SUITE 110
3. Date of Earliest Transaction (MM/DD/YYYY)
8/3/2020
(Street)
WESTLAKE VILLAGE, CA 91361
(City)       (State)       (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)
 
6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock  8/3/2020    A    33500 (1) A $0  33500 (2) D   

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy)  $25.89  8/3/2020    A     320000       (3) 8/3/2030  Common Stock  320000  $0.00  320000  D   

Explanation of Responses:
(1)  Grant of Restricted Stock Units ("RSU"). The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof.
(2)  Includes 33,500 RSUs. The RSUs will begin vesting upon the achievement of the performance-based milestones.
(3)  The option vests as to 1/4 of the total shares on August 1, 2021, and then 1/48 of the total shares vest monthly thereafter, with 100% of the total shares vested on August 1, 2024, subject to the Reporting Person's provision of service to the Issuer on each vesting date.

Remarks:
Senior Vice President and Chief Medical Officer

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Burnett Patrick
C/O ARCUTIS BIOTHERAPEUTICS, INC.
2945 TOWNSGATE ROAD SUITE 110
WESTLAKE VILLAGE, CA 91361


See Remarks

Signatures
/s/ John W. Smither, as Attorney-in-Fact for Patrick Burnett 8/5/2020
**Signature of Reporting Person Date
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more Arcutis Biotherapeutics Charts.
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more Arcutis Biotherapeutics Charts.